



[Home](#) / [Investors](#) / [Press Releases](#)

## Insmmed to Present at 31st Annual J.P. Morgan Healthcare Conference

MONMOUTH JUNCTION, N.J., Dec. 13, 2012 /PRNewswire/ -- Insmmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases, today announced that the Company will be participating in the 31st Annual J.P. Morgan Healthcare Conference from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco. Will Lewis, Insmmed's President and CEO, will present a corporate overview on Thursday, January 10th at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).

A live audio webcast of Mr. Lewis' presentation will be made available in the Investor section of Insmmed's website, <http://www.insmed.com> where it will be archived for 90 days.

Insmmed management will be available for one-on-one meetings with investors and analysts throughout the conference from January 7-10, 2013. To schedule an appointment, contact Anne Marie Fields of LHA at 212-838-3777 or [afields@lhai.com](mailto:afields@lhai.com) or contact your J.P. Morgan representative.

### About Insmmed

Insmmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient populations with critical unmet needs. Insmmed's lead candidate, ARIKACE®, is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for at least two identified patient populations: cystic fibrosis (CF) patients with *Pseudomonas aeruginosa* lung infections and patients with nontuberculous mycobacteria lung infections (NTM). Following positive phase 2 results in CF patients, Insmmed's phase 3 registrational study of ARIKACE (CLEAR-108) in Europe and Canada has completed enrollment, and the Company expects top-line clinical results in mid-2013. Insmmed's U.S. phase 2 clinical trial in NTM (TARGET-NTM) is well under way with clinical results expected in late 2013. The Company is currently preparing for regulatory filings and for commercialization, if and when regulatory approvals are obtained. For more information, please visit <http://www.insmed.com>.

### Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Words, and variations of words, such as "intend", "expect", "will", "anticipate", "believe", "continue", "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data and the anticipated benefits of Insmmed's products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting our product development, delays in product development or clinical trials, patent disputes involving currently developing products, unexpected regulatory actions, delays or requests, the failure of future clinical trials, inability to successfully develop our product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to update these forward-looking statements to reflect events or circumstances or changes in our expectations.

### Investor Relations Contact:

LHA  
Anne Marie Fields  
Senior Vice President  
212-838-3777  
[afields@lhai.com](mailto:afields@lhai.com)

Bruce Voss  
Managing Director  
310-691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

---